Compare MXC & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXC | GTBP |
|---|---|---|
| Founded | 1972 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 17.7M |
| IPO Year | 1995 | 2016 |
| Metric | MXC | GTBP |
|---|---|---|
| Price | $7.51 | $0.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.5K | ★ 1.3M |
| Earning Date | 02-10-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $2,705,235.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.92 | ★ N/A |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $7.16 | $0.26 |
| 52 Week High | $16.48 | $2.86 |
| Indicator | MXC | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 53.62 |
| Support Level | N/A | $0.38 |
| Resistance Level | $9.56 | $0.57 |
| Average True Range (ATR) | 0.46 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 46.41 | 41.53 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.